ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ascendis Pharma A/S
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 11, 2026
$229.95+4.70 (+2.09%)
Close on Oct 19, 2026
Ascendis Pharma A/S revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | €546.39M | €233.12M | €191.68M | – | – | – | – | – | €1.53M | €4.61M | 75.9% | +134.4% |
| Europe [member] | €120.95M | €123.34M | €869.00K | €552.00K | – | – | – | – | – | – | 16.8% | -1.9% |
| Rest of World [member] | €52.80M | €7.19M | €74.17M | €6.47M | – | – | – | – | – | – | 7.3% | +634.3% |
| Denmark | €12.90M | €95.40M | €0 | – | – | – | – | – | – | – | 1.8% | -86.5% |
| North America [member] | – | €233.22M | €191.68M | €44.16M | €6.86M | €2.68M | €2.65M | €10.58M | €1.53M | €4.61M | – | – |
| Denmark [member] | – | – | – | – | – | – | – | €0 | – | – | – | – |
| China | – | – | – | €6.47M | €922.00K | €4.27M | €10.72M | – | – | – | – | – |
| Asia [Member] | – | – | €74.17M | €6.47M | €922.00K | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Ascendis Pharma A/S's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.